ALLR (Allarity Therapeutics) 6-Month Price Index: 0.93 (As of Sep. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALLR Allarity Therapeutics Inc ALLR
23 GF Score
Price $1.13
! 2 Warning Signs
View Full Analysis

What is Allarity Therapeutics 6-Month Price Index?

Allarity Therapeutics ALLR -5.13% 23 6-Month Price Index is 0.93 as of Sep. 15, 2026. GuruFocus rates ALLR with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-09-15), Allarity Therapeutics's 6-Month Price Index is 0.93.

Allarity Therapeutics  (NAS:ALLR) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Allarity Therapeutics 6-Month Price Index Related Terms

ALLR vs ABVC, MRKR, CNSY: 6-Month Price Index Comparison

For the Biotechnology subindustry, Allarity Therapeutics's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ALLR
23GF Score
Allarity Therapeutics Inc ALLR
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Allarity Therapeutics  (NAS:ALLR) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 0.93 mean?
Allarity Therapeutics (ALLR) has a 6-Month Price Index of 0.93 as of Sep. 15, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Allarity Therapeutics and its competitors.
Is Allarity Therapeutics' 6-Month Price Index too high?
Allarity Therapeutics' current 6-Month Price Index is 0.93. Overall, Allarity Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Allarity Therapeutics' 6-Month Price Index compare to ABVC and MRKR?
Allarity Therapeutics' 6-Month Price Index of 0.93 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Biotechnology company?
A good 6-Month Price Index depends on the Biotechnology industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Allarity Therapeutics and its competitors. Allarity Therapeutics's current 6-Month Price Index is 0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allarity Therapeutics stock overvalued right now?
Allarity Therapeutics (ALLR) has a current 6-Month Price Index of 0.93. The current 6-Month Price Index is 0.93. Allarity Therapeutics' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Allarity Therapeutics (ALLR), the current 6-Month Price Index is 0.93 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Allarity Therapeutics Business Description

Address 123 East Tarpon Avenue, Tarpon Springs, FL, USA, 34689
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
23GF Score

Get the complete analysis for ALLR

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.13
Price